Exelixis (EXEL) Stock up +9 Percent on FDA Approval

Shares of Exelixis Inc. (EXEL) were up +0.39 or +8.37 percent in Tuesday's premarket after the company announced that the FDA had approved the company's lead cancer drug cabozanitinib, which will be marketed under the brand name CABOMETYX. Exelixis stock closed at $4.66 per share, up +0.25 or +5.67 percent in Monday's regular trading session. ... READ MORE Read the rest of Exelixis (EXEL) Stock up +9 Percent on FDA Approval at InvestorGuide.com .